Denali Therapeutics (NASDAQ:DNLI) Given New $24.00 Price Target at Wedbush

Denali Therapeutics (NASDAQ:DNLI) had its price target raised by investment analysts at Wedbush from $23.00 to $24.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Wedbush‘s price objective would suggest a potential upside of 23.39% from the stock’s previous close.

Several other brokerages also recently issued reports on DNLI. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a report on Thursday, October 15th. Morgan Stanley upped their target price on shares of Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Wall Street Zen upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Finally, JPMorgan Chase & Co. started coverage on Denali Therapeutics in a report on Monday, July 13th. They set an “overweight” rating and a $29.00 price target on the stock. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.69.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $19.45 on Wednesday. The stock has a market cap of $3.11 billion, a P/E ratio of -6.85 and a beta of 1.08. Denali Therapeutics has a twelve month low of $13.75 and a twelve month high of $27.30. The stock has a 50 day moving average of $20.42 and a two-hundred day moving average of $21.24. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Tuesday, November 3rd. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.64. The business had revenue of $17.78 million for the quarter, compared to analysts’ expectations of $12.67 million. During the same quarter last year, the business posted ($0.74) earnings per share. On average, research analysts forecast that Denali Therapeutics will post -2.70 earnings per share for the current year.

Insider Activity at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,768 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $23.44, for a total transaction of $64,881.92. Following the completion of the sale, the insider directly owned 278,995 shares of the company’s stock, valued at $6,539,642.80. This trade represents a 0.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Denali Therapeutics

A number of large investors have recently bought and sold shares of DNLI. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Denali Therapeutics in the second quarter valued at about $26,000. Global Retirement Partners LLC purchased a new position in Denali Therapeutics during the second quarter worth about $28,000. Nykredit A S purchased a new position in Denali Therapeutics during the second quarter worth about $38,000. Manchester Capital Management LLC raised its holdings in Denali Therapeutics by 5,505.6% during the third quarter. Manchester Capital Management LLC now owns 2,018 shares of the company’s stock worth $42,000 after purchasing an additional 1,982 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Denali Therapeutics by 44.4% in the third quarter. GAMMA Investing LLC now owns 2,236 shares of the company’s stock valued at $46,000 after purchasing an additional 687 shares during the period. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Key Headlines Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: AVLAYAH generated $17.8 million in net product revenue in its second full commercial quarter. Denali forecast fourth-quarter revenue of $30 million to $32 million, signaling expected acceleration in sales. Denali Q3 2026 results
• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set a $39 price target, substantially above the cited current price of $19.45. BTIG Research ratings
• Positive Sentiment: Denali said its zafinofusp BLA submission remains on track for 2027, and expects data in 2027 from five TransportVehicle programs. These milestones offer potential future catalysts, though they remain subject to development and regulatory risk. Denali Q3 2026 results
• Negative Sentiment: Quarterly net income of $70.1 million included a one-time $194 million gain from selling a Priority Review Voucher, so it may overstate recurring earnings strength. Zacks separately reported a $0.64 per-share loss, narrower than expected and improved from a year earlier. Zacks Q3 earnings report

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.